Small-cell lung cancer (SCLC) remains a therapeutic challenge, from both a biomedical and quality of life point of view. The majority of patients respond to combination chemotherapy resulting in a four-to 5-fold prolongation of median survival, but only a small proportion survive diseasefree over a period of more than 2 years. In responders, early chemotherapy is expected to have a beneficial impact on physical functioning and subjective well-being by alleviation of tumour symptoms.
However, the majority of patients who initially respond to treatment will become refractory to therapy and die of their disease. In clinical decision-making, the evaluation of the trade-off between a potential gain in survival time and a potential loss in quality of life (QL) owing to treatment toxicity is a subtle task (Bergman and Aaronson, 1995) . For biomedical outcome, well-established prognostic factors facilitate decision-making. In contrast, for QL outcome, no systematic data on prognostic factors are, to our knowledge, available.
It can be anticipated that QL is substantially predicted by biomedical as well as psychosocial variables, such as the coping process, social support and psychiatric history (Bernhard and Ganz, 1995) . These need more investigation, and would require a standard assessment to be systematically included in trials to improve decision-making. As a result of the prognostic value of biomedical factors for survival, it is of particular interest to evaluate whether they also predict QL outcome, i.e. whether better (worse) initial prognostic factors are a priori associated with better (worse) QL under chemotherapy. We investigated the predictive value of tumour stage, performance status, previous weight loss, sex and age at diagnosis for QL during chemotherapy in a controlled clinical trial (SAKK protocol 15/84) comparing early and late alternating chemotherapy (Joss et al., 1995b) .
Different methods for examining and analysing longitudinal QL data are presented. As suggested by the Medical
Research Council (MRC) Lung Cancer Working Party (Hopwood et al., 1994) 
Statistical methods
The pattern of change in QL data is difficult to analyse (Hopwood et al., 1994) . QL assessments result in several data points for each patient, and multiple analyses may result in invalid conclusions (Fletcher et al., 1992) . One technique for dealing with longitudinal data is repeated measure analysis (Davis, 1991) , which requires complete and normally distributed data sets. In order to detect even moderate differences, large sample sizes are necessary. In the present study, only few patients had a complete set of assessments.
As an alternative to repeated measure analysis, we d,fined summary measures (Matthews, 1993) Results Patient characteristics and QL compliance As detailed elsewhere, the average rate of returned questionnaires with an exact timing over the six cycles was 49% (Hurny et al., 1992) . With the extended time window, 54-56% of expected scale scores were available. The subgroup with QL data was compared with the one without and no significant differences were found regarding biomedical data (Bernhard, 1992) . The number of evaluable patients/assessments differed between the four scales (Tables I  and II) . The overall and limited samples had a similar distribution of patient characteristics; the two treatment groups were balanced.
Overall sample Levels of initial tumour stage, performance status and weight loss discriminated the average scores of each scale during all cycles. Patients with poor prognostic factors reported worse scores (i.e. higher scores), as shown for emotional well-being (Bf-S) in Figure 1 .
The summary measure for 'overall' QL was also predicted in all scales by initial prognostic factors in multivariate analyses (Table I) and older patients reported worse general well-being.
Cycle Figure 1 Overall sample: emotional well-being (Bf-S) over six cycles by levels of initial prognostic factors (±2s.e.). Average scores are connected through time points to facilitate visual comparisons; they are based on different sample sizes.
Pattern of QL over cycles (graphical representation)
In the graphical representation patients with poor initial prognostic factors again showed worse QL. Those with in Figure 4 for general and emotional well-being. Older patients reported worse fatigue/malaise and general wellbeing. In addition, they showed a tendency to improve later than younger patients. (Coates et al., 1987) .
In addition to symptom alleviation, treatment is usually associated with hope and supports particular patients in coping with their anxiety of fatal outcome. However, the optimal balance between treatment intensity, biomedical and QL outcome needs further specification. According to the present knowledge and our data, patients with limited disease benefit subjectively, in terms of their QL, from the currently available, intensive and regularly scheduled, standard chemotherapy regimens, as toxic side-effects are largely outweighed by improvement of tumour-related symptoms and therefore general well-being. These patients should be treated accordingly.
In patients with extensive disease, especially the elderly, the choice of treatment is more difficult. As their QL is substantially improving, mainly during the first three treatment cycles, but does not reach the level observed in limited-disease patients even after response, a conceivable treatment option could be to treat these patients intensively to maximum response and to continue with a milder maintenance therapy including best supportive care. This option has to be tested in a randomised clinical trial against intensive standard chemotherapy, as used for patients with limited disease.
A
In the present analysis, we have chosen four QL measures sensitive to both disease symptoms and treatment side-effects and giving an overall estimation of patients' physical and psychological well-being (Bernhard, 1992) . All were sensitive to initial prognostic factors but showed distinct patterns, which may be explained by their different concepts and time frames. As in other QL trials in SCLC patients (Bleehen et al., 1989 (Bleehen et al., , 1993 Gower et al., 1995) , missing data limit this analysis, although summary measures revealed consistent findings among related subgroups and concepts. As drop-out rates increased with time, data were collected only from patients with a better health status. Thus, analyses of changes in QL may show, to a certain extent, an attrition bias (i.e. rapidly diminishing patient numbers). In addition, only major differences could be demonstrated owing to the small sample size and related reduced statistical power.
The potential underlying interactions between prognostic factors, treatment, course of disease and patient's adjustment process need further study, including improved methods for handling missing data and longitudinal analyses. Clinically, a high-risk group for poor adjustment is of particular concern, as suggested by a screening trial for psychological morbidity in advanced SCLC (Hopwood and Thatcher, 1990) . In addition, patients with poor performance status may find it too burdensome to participate actively in the treatment decision (Blanchard et al., 1988) .
In conclusion, initial tumour stage, performance status and previous weight loss can predict QL during chemotherapy, even after controlling for response to treatment. To determine the optimal balance between treatment intensity, efficacy and QL in SCLC remains a challenge. Prognostic factors for psychosocial outcome should be investigated further, possibly providing additional information for the difficult decision of how to treat SCLC patients with extensive disease.
